Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting Journal Article

   


Authors: Rajanala, S. H.; Ghale, R.; Nandakumar, S.; Chadalavada, K.; Lee, G. S. M.; Stopsack, K. H.; Chen, Y.; Nanjangud, G. J.; Chakraborty, G.; Kantoff, P. W.
Article Title: Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting
Abstract: Somatic Y chromosome loss in hematopoietic cells is associated with higher mortality in men. However, the status of the Y chromosome in cancer tissue is not fully known due to technical limitations, such as difficulties in labelling and sequencing DNA from the Y chromosome. We have developed a system to quantify Y chromosome gain or loss in patient-derived prostate cancer organoids. Using our system, we observed Y chromosome loss in 4 of the 13 (31%) patient-derived metastatic castration-resistant prostate cancer (mCRPC) organoids; interestingly, loss of Yq (long arm of the Y chromosome) was seen in 38% of patient-derived organoids. Additionally, potential associations were observed between mCRPC and Y chromosome nullisomy. The prevalence of Y chromosome loss was similar in primary and metastatic tissue, suggesting that Y chromosome loss is an early event in prostate cancer evolution and may not a result of drug resistance or organoid derivation. This study reports quantification of Y chromosome loss and gain in primary and metastatic prostate cancer tissue and lays the groundwork for further studies investigating the clinical relevance of Y chromosome loss or gain in mCRPC. © 2024 Rajanala et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: immunohistochemistry; adult; clinical article; controlled study; human tissue; gene mutation; human cell; genetics; metastasis; gene expression; prevalence; pathology; dna methylation; docetaxel; prostate cancer; prostatic neoplasms; in situ hybridization; chromosome aberration; fluorescence in situ hybridization; prostate tumor; neoplasm metastasis; chromosomal instability; chromosome deletion; androgen deprivation therapy; chromosome loss; chromosome painting; follitropin; castration resistant prostate cancer; y chromosome; chromosome number; chromosomes, human, y; enzalutamide; humans; human; male; article; prostatic neoplasms, castration-resistant; metastatic castration resistant prostate cancer; organoids; robot assisted surgery; organoid
Journal Title: PLoS ONE
Volume: 19
Issue: 4
ISSN: 1932-6203
Publisher: Public Library of Science  
Date Published: 2024-04-29
Start Page: e0301989
Language: English
DOI: 10.1371/journal.pone.0301989
PUBMED: 38683764
PROVIDER: scopus
PMCID: PMC11057730
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191869469&doi=10.1371%2fjournal.pone.0301989&partnerID=40&md5=f8aecbea3286488293491c8fd1e993c6
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Yu Chen
    133 Chen
  2. Goutam Chakraborty
    45 Chakraborty
  3. Gouri J Nanjangud
    76 Nanjangud
  4. Kalyani Chadalavada
    23 Chadalavada
  5. Philip Wayne Kantoff
    198 Kantoff
  6. Konrad Hermann Stopsack
    70 Stopsack
  7. Subhiksha Nandakumar
    69 Nandakumar
  8. Sai Harisha Rajanala
    12 Rajanala
  9. Romina Ghale
    10 Ghale
Related MSK Work